Search

The reaction to drugs with eosinophilia and systemic symptoms called DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is part of a broad spectrum called toxicodermias. The exact incidence is not known in children; However, a mortality rate that can be as high as 10% has been estimated in the literature. We present the case of a teenage patient with a personal history of bipolar affective disorder (BD), who received sertraline, quetiapine and trazodone on an outpatient basis. Due to the presence of hallucinations, lithium was added to the management. Ten days later she went to the emergency department due to the appearance of a skin rash and systemic symptoms, for which a clinical condition secondary to hypersensitivity to medications was suspected. [ABSTRACT FROM AUTHOR]

Copyright of Revista Ciencias de la Salud is the property of Colegio Mayor de Nuestra Senora del Rosario and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Revista Colombiana de Psiquiatria is the property of Asociacion Colombiana de Psiquiatria and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Revista Colombiana de Psiquiatria is the property of Asociacion Colombiana de Psiquiatria and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Trazodone is a second generation, atypical antidepressant. It exerts selective inhibitory actions on the transport of serotonin (5-HT), in a lesser amount than the selective serotonin reuptake inhibitors. The most striking pharmacological effect is as a 5-HT2A y 5-HT2C antagonist. It also blocks the α1- α2 adrenergic and histamine-1 receptors. It is effective for depression, insomnia treatment and some anxiety disorders, either as monotherapy or in combination with other drugs. Albeit non-conclusive, it is also used as adjunctive therapy in some cases of mania, Tourette syndrome, Alzheimer's disease and schizophrenia. Trazodone has tried in the erectile dysfunction treatment given its blocking actions on the α-adrenoceptors, but its use is controversial from some reports of priapism. Trazodone has drug interactions with other antidepressants, and some neuroleptics, antimycotics and antiretroviral drugs, among others. The aim of this review is to describe the pharmacology of trazodone and its clinical uses and side effects. [ABSTRACT FROM AUTHOR]